ABSTRACT
Objectives To increase cervical cancer screening capacity and participation, we evaluated the performance of the newly developed hrHPV ReadyMix qPCR Kit for detecting high-risk Human Papillomavirus (HPV) in urine samples while simultaneously genotyping HPV16, HPV18, and HPV52.
Methods 876 samples were used to assess the performance of hrHPV ReadyMix qPCR Kit in detecting high-risk HPV in standard cervical swab sample compared to the Roche cobas® 6800 HPV. The high-risk HPV detection in urine was compared to the corresponding paired cervical swab.
Results The sensitivity of HPV detection in cervical swabs using hrHPV ReadyMix qPCR Kit reached 96.55% and the specificity reached 99.87%. Despite higher Ct values, urine samples demonstrated 80.88% sensitivity and 100.00% specificity compared to cervical swabs. Our method enables population-based high-risk HPV analysis with a 6.62% HPV prevalence from cervical swabs and 6.28% from urine samples. Furthermore, urine samples using the hrHPV ReadyMix qPCR Kit showed comparable HPV type distribution and the ability to genotype HPV16 and HPV18, to Roche the cobas® 6800 HPV.
Conclusions Self-collected urine samples offer a 98.48% diagnostic accuracy for detecting high- risk HPV infection. This study highlights the hrHPV ReadyMix qPCR Kit’s potential in enhancing cervical cancer screening, offering valuable insights for future interventions.
Competing Interest Statement
N.S.I., R.U., S.M.K., and M.R.R. are employees of Nusantics, PT Riset Nusantara Genetika. R.U. has financial holdings in Nusantics, PT Riset Nusantara Genetika. N.N. and R.M.S are employees at PT Bio Farma. The remaining authors declare that they have no conflict of interest.
Funding Statement
This study was funded by PT Bio Farma in terms of subject recruitment, sample processing, and human resources. PT Bio Farma has a role in the study design, subject recruitment, and decision to submit the paper for publication. The development of the hrHPV ReadyMix kit and the NGS method were funded by Nusantics, PT Riset Nusantara Genetika, which also has a role in the study design, data collection, analysis, interpretation, report writing, and the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Research Ethics Committee of the Faculty of Medicine Universitas Indonesia Dr. Cipto Mangunkusumo Hospital gave ethical approval of this work under the identifier No. KET- 674 / UN2.F1/ETIK/PPM.00.02/2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Updated title on the manuscript, grammatical error correction, and references update
